464
Participants
Start Date
November 30, 2011
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
MEDI8968 600 mg IV, 300 mg SC
MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
Placebo
Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
Research Site, Peoria
Research Site, Clearwater
Research Site, Duluth
Research Site, Auburn
Research Site, Buffalo
Research Site, Charlotte
Research Site, Cincinnati
Research Site, Oklahoma City
Research Site, Greenville
Research Site, Spartanburg
Research Site, Boerne
Research Site, Richmond
Research Site, Plovdiv
Research Site, Rousse
Research Site, Sofia
Research Site, Stara Zagora
Research Site, Veliko Tarnovo
Research Site, Brno
Research Site, Jindřichův Hradec
Research Site, Karlovy Vary
Research Site, Pilsen
Research Site, Prague
Research Site, Strakonice
Research Site, Balassagyarmat
Research Site, Budapest
Research Site, Farkasgyepü
Research Site, Komárom
Research Site, Mátészalka
Research Site, Mátraháza
Research Site, Mosonmagyaróvár
Research Site, Nagykanizsa
Research Site, Szikszó
Research Site, Tatabánya
Research Site, Törökbálint
Research Site, Daugavpils
Research Site, Riga
Research Site, Kaunas
Research Site, Klaipėda
Research Site, Vilnius
Research Site, Iloilo City
Research Site, Lipa City
Research Site, Quezon City
Research Site, Bialystok
Research Site, Gdansk
Research Site, Krakow
Research Site, Lodz
Research Site, Oświęcim
Research Site, Poznan
Research Site, Wroclaw
Research Site, Zgierz
Research Site, Ivano-Frankivsk
Research Site, Kharkiv
Research Site, Kyiv
Research Site, Odesa
Research Site, Poltava
Research Site, Simferopol
Research Site, Vinnytsia
Research Site, Cambridge
Research Site, Newcastle upon Tyne
Research Site, Wolverhampton
Lead Sponsor
MedImmune LLC
INDUSTRY